1333Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year
نویسندگان
چکیده
1333. Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year Anna Wald, MD, MPH, FIDSA; Terri Warren, ANP; Kenneth Fife, MD, PhD; Stephen Tyring, MD, PhD; Patricia Lee, MD; Nicholas Van Wagoner, MD, PhD; David Bernstein, MD; Jessica B. Flechtner, PhD; Amalia Magaret, PhD; Amy Morris,; Seth Hetherington, MD; Department of Medicine, University of Washington, Seattle, WA; Westover Heights Clinic, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Center for Clinical Studies, Houston, TX; Center for Clinical Studies, Webster, TX; Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; Genocea Biosciences, Cambridge, MA; Departments of Laboratory Medicine and Biostatistics, University of Washington; Fred Hutchinson Cancer Research Center, Seattle, WA; IND2Results, Atlanta, GA
منابع مشابه
Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines".
At an NIAID workshop entitled “Next Generation Herpes Simlex Virus Vaccines: The Challenges and Opportunities” on October 2–23, 2012, researchers agreed that there was a great medical eed for a herpes simplex virus (HSV) vaccine and recommended ncreased focus on all stages of herpes vaccine research, develpment, and testing, including basic vaccine discovery research, evelopment and manufacturi...
متن کاملEfficacy results of a trial of a herpes simplex vaccine.
BACKGROUND Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not observed in men or HSV-1 seropositive women. METHODS We conducted a randomized, double-blind efficacy fiel...
متن کاملProtection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
A prophylactic vaccine for genital herpes disease remains an elusive goal. We report the results of two studies performed collaboratively in different laboratories that assessed immunogenicity and vaccine efficacy in herpes simplex virus 1 (HSV-1)-seropositive guinea pigs immunized and subsequently challenged intravaginally with HSV-2. In study 1, HSV-2 glycoproteins C (gC2) and D (gD2) were pr...
متن کاملA trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model
An estimated 417 million people worldwide ages 15 to 49 are infected with herpes simplex virus type 2 (HSV-2), the most common cause of genital ulcer disease. Some individuals experience frequent recurrences of genital lesions, while others only have subclinical infection, yet all risk transmitting infection to their intimate partners. A vaccine was developed that prevents shingles, which is a ...
متن کاملEpidemiology of recurrent genital herpes simplex virus types 1 and 2.
OBJECTIVES To describe the epidemiology of type specific recurrent genital herpes, and to compare the duration of recurrent genital lesions caused by herpes simplex virus (HSV) types 1 and 2. METHODS Participants were enrolled at clinics across the United States. Adults suspected of having active genital herpes were eligible. Lesions were cultured for HSV and typed. Data from 940 participants...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2014